Primo studio sull'uomo su CDR404 in partecipanti HLA-A*02:01 con tumori solidi che esprimono MAGE-A4
Fase 1, primo studio sull'uomo per valutare la sicurezza, la tollerabilità e l'attività antitumorale di CDR404 nei partecipanti HLA-A*02:01 con tumori solidi che esprimono MAGE-A4
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases:
- To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404
- To assess preliminary evidence of anti-tumor activity of CDR404
- To characterise the pharmacokinetics of CDR404
- To characterise the immunogenicity of CDR404
- To assess translational biomarkers
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Antwerp, Belgio, 2650
- Universitair Ziekenhuis Antwerpen
-
Brussels, Belgio, 1070
- Institut Jules Bordet
-
Brussels, Belgio, 1200
- Cliniques Universitaires Saint-Luc, UCL Ouvain
-
Ghent, Belgio, 9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Copenhagen, Danimarca, DK-2100
- Rigshospitalet
-
-
-
-
-
Milan, Italia, 20089
- Istituto Clinico Humanitas
-
Milan, Italia, 20141
- Isituto Europeo di Oncologia (IEO)
-
-
-
-
-
Glasgow, Regno Unito
- The Beatson West of Scotland Cancer Center
-
London, Regno Unito
- Guys and St Thomas' NHS Foundation Trust
-
-
London
-
Sutton, London, Regno Unito, SM2 5PT
- Royal Marsden Hospital
-
-
-
-
-
Barcelona, Spagna, 08035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spagna, 08908
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
-
Madrid, Spagna, 28041
- Hospital 12 de Octubre
-
Madrid, Spagna, 28050
- START Madrid
-
Valencia, Spagna, 46026
- Hospital Universitari i Politecnic La Fe
-
Valencia, Spagna, 46026
- Instituto de Investigacion Sanitaria (INCLIVA)
-
-
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Providence Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19106
- Pennsylvania Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Provision of written informed consent
- HLA-A*02:01 positive
- MAGE-A4 positive tumor
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
- Selected advanced solid tumors
- Relapsed from, refractory to, or intolerant of standard therapy
- Measurable disease per RECIST v1.1
- Adequate organ function
- If applicable, must agree to use highly effective contraception
Exclusion Criteria:
- Symptomatic or untreated central nervous system metastasis
- Inadequate washout from prior anticancer therapy
- Significant ongoing toxicity from prior anticancer treatment
- Recent surgery
- Clinically significant cardiac disease
- Active infection requiring systemic antibiotic treatment
- Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes
- Active hepatitis B virus (HBV) or hepatitis C virus (HBC)
- Ongoing treatment with systemic steroids or other immunosuppressive therapies
- Significant secondary malignancy
- History of chronic or recurrent active autoimmune disease requiring treatment
- Uncontrolled intercurrent illness
- Pregnancy or lactation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: CDR404
Dose escalation |
IV infusions |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Presence of dose limiting toxicities (DLTs)
Lasso di tempo: From first dose to DLT period (21 days)
|
per Protocol |
From first dose to DLT period (21 days)
|
|
Incidence and severity of (serious) adverse events ([S]AEs)
Lasso di tempo: From first dose to 90 days after the last dose
|
AEs, SAEs |
From first dose to 90 days after the last dose
|
|
Anti-tumor response: Overall Response Rate (ORR)
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease control rate (DCR)
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Duration of response (DOR)
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Progression-free Survival (PFS)
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Overall Survival (OS)
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
per RECIST 1.1 |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
|
Maximum serum concentration of CDR404 (Cmax)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Time to maximum serum concentration of CDR404 (Tmax)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Trough serum concentration of CDR404 (Ctrough)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Half-life of CDR404 (t1/2)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Area under the CDR404 serum concentration over time curve (AUC0-T)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
to the end of the dosing interval following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Volume of CDR404 distribution (Vd)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Average serum concentration of CDR404 (Cavg)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Serum drug levels of CDR404 at steady state (CL)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Accumulation ratio of CDR404 (Rac)
Lasso di tempo: At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
following single and multiple dose administration |
At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
|
|
Immunogenicity
Lasso di tempo: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Incidence of detectable anti-CDR404 antibodies (ADAs) |
From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CDR404-001
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .